Alexion Pharmaceuticals

Alexion Pharmaceuticals

Verified
Alexion Pharmaceuticals, Inc (NASDAQ: ALXN) | World Leader in Treatments for Patients with Devastating and Rare Diseases

Financials

Edit
Revenues, earnings & profits over time
USD2016201720182019202020212022E
Revenues-3.6b4.1b5.0b6.1b6.6b7.2b
% growth--16 %21 %22 %10 %8 %
EBITDA-2.1b2.6b3.2b3.7b4.0b4.0b
% EBITDA margin-59 %63 %63 %61 %60 %56 %
Profit-443m77m2.4b603m2.5b2.8b
% profit margin-12 %2 %48 %10 %38 %38 %
R&D budget790m805m702m868m---
R&D % of revenue-23 %17 %17 %---

Source: Company fillings or news article

  • Edit
DateInvestorsAmountRound
-N/A-
Not yet verified
N/AN/AIPO
N/ARSD3.5mSeed
$39.0b
Valuation: $39.0b
Acquisition
Total Funding$38.5k

Recent News about Alexion Pharmaceuticals

Edit

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.

Investments by Alexion Pharmaceuticals

Edit
Synageva BioPharma
ACQUISITION by Alexion Pharmaceuticals May 2015
Taligen Therapeutics
ACQUISITION by Alexion Pharmaceuticals Jan 2011
Enobia Pharma
ACQUISITION by Alexion Pharmaceuticals Dec 2011
Achillion Pharmaceuticals
ACQUISITION by Alexion Pharmaceuticals Oct 2019
Portola Pharmaceuticals
ACQUISITION by Alexion Pharmaceuticals May 2020
Wilson Therapeutics
ACQUISITION by Alexion Pharmaceuticals Apr 2018